{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:12:26Z","timestamp":1785510746185,"version":"3.56.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Omadacycline is a novel aminomethylcycline antibiotic that shows non\u2010inferior efficacy to moxifloxacin in adults with community\u2010acquired pneumonia (CAP), but lacking clinical evidence in elderly patients with CAP. This randomized, controlled study aimed to investigate the efficacy and safety of omadacycline in elderly patients with CAP. Eligible elderly patients with CAP were randomized at a 1:1 ratio to the omadacycline group (n = 48) and moxifloxacin group (n = 49) to receive the corresponding agent. The primary endpoint was clinical response. The most common pathogens in the omadacycline and moxifloxacin groups were\n                    <jats:italic>viridans streptococci<\/jats:italic>\n                    (16.7%, 16.3%),\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    (14.6%, 14.3%), and\n                    <jats:italic>Neisseria sicca<\/jats:italic>\n                    (14.6%, 14.3%). Clinical response rate was greater in the omadacycline group compared to the moxifloxacin group (54.2% vs 26.5%,\n                    <jats:italic>P<\/jats:italic>\n                    = \u00a0.032). The omadacycline group showed higher significant improvement rate (41.7% vs 16.3%,\n                    <jats:italic>P<\/jats:italic>\n                    = \u00a0.02), but similar complete recovery (12.5% vs 10.2%,\n                    <jats:italic>P<\/jats:italic>\n                    = \u00a0.737), effective improvement (37.5% vs 59.2%,\n                    <jats:italic>P<\/jats:italic>\n                    = \u00a0.125), and ineffectiveness (8.3% vs 14.3%,\n                    <jats:italic>P<\/jats:italic>\n                    = \u00a0.384) rates compared to the moxifloxacin group. Results of C\u2010reactive protein, procalcitonin, and interleukin\u20106 at baseline and after treatment, as well as their changes did not vary between the omadacycline and moxifloxacin groups (all\n                    <jats:italic>P<\/jats:italic>\n                    &gt; \u00a0.05). No difference was observed in liver, kidney, and coagulation function parameters between the two groups (all\n                    <jats:italic>P<\/jats:italic>\n                    &gt; \u00a0.05). Omadacycline indicates greater treatment efficacy and comparable safety profiles versus moxifloxacin in elderly patients with CAP.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.1627","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:57:08Z","timestamp":1763715428000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Efficacy and Safety Profiles Between Omadacycline and Moxifloxacin in Elderly Patients with Community\u2010Acquired Pneumonia: A Randomized, Controlled Trial"],"prefix":"10.1002","volume":"15","author":[{"given":"Muming","family":"Yu","sequence":"first","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Wang","sequence":"additional","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Wu","sequence":"additional","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancun","family":"Liu","sequence":"additional","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Chai","sequence":"additional","affiliation":[{"name":"Emergency Department Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00630-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01248-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00031-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14796"},{"key":"e_1_2_10_6_1","volume-title":"Moxifloxacin","author":"Humma ZE","year":"2024"},{"issue":"1","key":"e_1_2_10_7_1","first-page":"18","article-title":"Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)","volume":"48","author":"Respiratory Branch of Chinese Geriatrics Society","year":"2025","journal-title":"Chin J Tuberc Respir Dis"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-017-0841-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S401807"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01257-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718823730"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1015-2"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00843-4"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab136"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.01.032"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab135"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2663-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_1678_19"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018818094"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1225710"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106442"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106263"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2185"},{"key":"e_1_2_10_25_1","unstructured":"Omadacycline.LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases;2012."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz398"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13337"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1627","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:48:50Z","timestamp":1774360130000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpdd.1627"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1627","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1627"}}